BeOne Medicines (BEIGF) Raw Materials (2024 - 2026)

BeOne Medicines (BEIGF) has reported Raw Materials for 3 consecutive years, with $267.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Raw Materials changed N/A year-over-year to $267.3 million in Q2 2026; TTM through Jun 2026 was $267.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $236.2 million, up 38.46% from the prior year.
• Raw Materials was $267.3 million for Q2 2026 at BeOne Medicines, down from $274.2 million in the prior quarter.
• Over five years, Raw Materials peaked at $274.2 million in Q1 2026 and troughed at $170.6 million in Q4 2024.
• A 3-year average of $237.1 million and a median of $251.7 million in 2025 frame the typical range for Raw Materials.
• The widest YoY moves for Raw Materials: up 38.46% in 2025, down 38.46% in 2025.
• Over 3 years, Raw Materials stood at $170.6 million in 2024, then surged by 38.46% to $236.2 million in 2025, then advanced by 13.16% to $267.3 million in 2026.
• The last three Raw Materials figures came in at $267.3 million (Q2 2026), $274.2 million (Q1 2026), and $236.2 million (Q4 2025), per Business Quant data.